- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00652808
Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg Once Daily and Naproxen 500 mg Twice Daily in Treating the Signs and Symptoms of Osteoarthritis of the Knee
April 7, 2008 updated by: Pfizer
Double-Blind, Double Dummy, Randomized Comparison Study to Evaluate the Efficacy and Safety of Valdecoxib 10 mg QD and Naproxen 500 mg BID in Treating the Signs and Symptoms of Osteoarthritis of the Knee
This study was performed to demonstrate that treatment with valdecoxib 10 mg daily (QD) was at least as effective as with naproxen 500 mg twice daily (BID), a standard non-steroidal anti-inflammatory drug (NSAID), when taken for 6 weeks in Korean subjects with symptomatic osteoarthritis (OA) of the knee.
Secondary objectives were to assess the overall safety and tolerability of valdecoxib 10 mg QD taken for 6 weeks in Korean subjects with symptomatic OA of the knee.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
265
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Anyang, Korea, Republic of, 431-070
- Pfizer Investigational Site
-
Gwangju, Korea, Republic of, 501-757
- Pfizer Investigational Site
-
Incheon, Korea, Republic of, 405-760
- Pfizer Investigational Site
-
Pusan, Korea, Republic of, 602-739
- Pfizer Investigational Site
-
Seoul, Korea, Republic of, 138-736
- Pfizer Investigational Site
-
Seoul, Korea, Republic of, 110-744
- Pfizer Investigational Site
-
Seoul, Korea, Republic of, 137-701
- Pfizer Investigational Site
-
Seoul, Korea, Republic of, 152-703
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Korean outpatients with symptomatic radiologic evidence of OA of the knee (diagnosed according to the modified American College Rheumatology criteria)
- Patient's Assessment of Arthritis Pain measurement of at least 40 mm on VAS
- Patients had not received any NSAIDs or analgesics within 2 days (within 4 days for subjects taking oxaprozin, piroxicam or full dose aspirin) prior to the Baseline Visit
Exclusion Criteria:
- Diagnosis of inflammatory arthritis, gout, pseudogout, Paget's disease, or any chronic pain syndrome that, in the Investigator's opinion, would interfere with the assessment of the Index Knee
- Symptomatic anserine bursitis or acute joint trauma of the Index Knee
- Arthroscopy performed on the Index Knee within the past 12 months
- Complete loss of articular cartilage of the Index Knee
- Administration of oral, or intramuscular, intravenous, or soft tissue injections of corticosterosteroids within 4 weeks prior to screening visit
- Administration of intra-articular injection of corticosteroids or hyaluronic acid preparation in the Index Knee within 3 months or 6 months, respectively
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 2
|
naproxen 500 mg capsule by mouth twice daily for 6 weeks
|
Active Comparator: Arm 1
|
valdecoxib 10 mg tablet by mouth once daily for 6 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)
Time Frame: Week 6
|
Week 6
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
WOMAC OA Physical Function
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC OA Stiffness Index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
Patient's Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)
Time Frame: Week 2
|
Week 2
|
Patient's Global Assessment of Arthritis Pain using a Visual Analogue Scale (OA-Pain VAS)
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
adverse events
Time Frame: Continuous
|
Continuous
|
Physician's Global Assessment of Arthritis Pain
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) Osteoarthritis (OA) Composite Index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
WOMAC OA Pain Index
Time Frame: Week 2 and Week 6
|
Week 2 and Week 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Study Completion (Actual)
September 1, 2004
Study Registration Dates
First Submitted
April 1, 2008
First Submitted That Met QC Criteria
April 3, 2008
First Posted (Estimate)
April 4, 2008
Study Record Updates
Last Update Posted (Estimate)
April 10, 2008
Last Update Submitted That Met QC Criteria
April 7, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Osteoarthritis, Knee
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Cyclooxygenase 2 Inhibitors
- Gout Suppressants
- Naproxen
- Valdecoxib
Other Study ID Numbers
- A3471045
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on valdecoxib
-
PfizerCompletedPain | Hallux ValgusUnited States
-
PfizerCompletedPain, Post-surgicalUnited States
-
PfizerCompletedPainCanada, United States, Belgium, Italy, Spain, Sweden, Colombia, Germany, Poland, Australia, Netherlands, Switzerland, Israel, Denmark, Singapore, South Africa, Ireland, United Kingdom, Czech Republic, Finland, Slovakia, Argentina, A... and more
-
Penn State UniversityPfizer; National Institutes of Health (NIH)CompletedPain | HyperalgesiaUnited States
-
PfizerCompletedPain | Sprains and Strains | SprainChile, Mexico, Argentina, Colombia, Peru
-
PfizerCompletedPain, PostoperativeKorea, Republic of, Thailand, Hong Kong, Taiwan, Singapore, New Zealand, Philippines, Australia, Malaysia
-
PfizerCompletedLow Back PainChile, Venezuela, Ecuador, Colombia, Brazil, Mexico, Argentina, Peru, Costa Rica
-
PfizerCompleted
-
University of WashingtonPfizerCompleted